Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247349 · ClinicalTrials.gov registry record · Phase 1
BMS-986012 in Relapsed/Refractory SCLC
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT02247349 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 106 participants.
The verdict
NCT02247349, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL BMS-986012 (anti-fucosyl-GM1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-11-14 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02247349
The ClinicalTrials.gov registry entry for NCT02247349 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02247349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02247349 about?
NCT02247349 is a clinical study titled "BMS-986012 in Relapsed/Refractory SCLC". The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
What is the current status of trial NCT02247349?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2014-11-14. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT02247349?
The interventions under investigation include: Nivolumab (BIOLOGICAL), BMS-986012 (anti-fucosyl-GM1) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02247349?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.